Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc.

 
APPEAL NO.
20-1723, 20-1901
OP. BELOW
DCT
SUBJECT
Patent
AUTHOR
Per Curiam

Question(s) Presented

“Whether a court is permitted to use the ‘prima facie’ framework to make a determination of obviousness before considering the objective indicia of non-obviousness, and then only look at those objective indicia to determine whether they are sufficient to ‘rebut’ the obviousness determination already made[.]”